FOR IMMEDIATE RELEASE
5th April 2019
Paola - Malta
CPTM to start the development of digital Clinical Decision Support Solutions (CDSS)
Cannapharm Technologies Malta Limited (“CPTM” or the “Company”) today announced the development of digital Clinical Decision Support Solutions (CDSS) supporting decision-making processes following the principles of personalised medicine.
“Clinical decision support systems are considered to be fundamental tools to gather genome, health and medical data and to help patients and healthcare professionals to use this data meaningfully” said Bruce H. Gaston, Director of CPTM. “The benefit to patients and doctors from CDSS is to improve health outcomes, reduce unneeded tests, eliminate drug-drug interactions and avoid unnecessary hospitalisations in the most effective and efficient way”.
The project will strive to integrate old and new scientific data into validated information and to convert this information into knowledge directly applicable to diagnosis, prognosis and treatment with cannabis-based drugs. Expanding into digital healthcare will provide new channels to promote the company's products, as well as pursuing our goal of providing patients with best-in-class, safe and effective cannabis-based therapy.
Bruce H. Gaston
Cannapharm Technologies Malta Limited (CPTM) is a limited company, registered under the Companies Act, 1995 of the Republic of Malta.
CPTM believes in long-term, incremental growth, based on the latest technological advances. It works closely with governments, regulatory authorities and local municipalities, to utilise, integrate and grow existing local infrastructures, within the framework of regional and governmental development programs and targets.
As an EU-based enterprise, CPTM adheres to and implements the strictest of standards in its productions, whilst maintaining a result-driven, qualitative approach to its pharmaceutical operations in Europe and Asia.